CARDINAL
Research type
Research Study
Full title
A Phase 1 Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants with Chronic Myeloid Leukemia
IRAS ID
1012460
Contact name
Karen Hodsdon
Contact email
Sponsor organisation
Terns, Inc
Clinicaltrials.gov Identifier
Research summary
Chronic myeloid leukaemia (CML) is a rare type of blood cancer. TERN-701 is a medication made by Terns, Inc., that can block a protein called BCR:: ABL1, an abnormal protein that causes CML by causing the cancer cells to multiply and grow.
TERN-701 is being evaluated in this clinical study to see if it can be given safely and stop or reduce the growth of cancer cells in people with CML who have previously received other treatments for CML that have either failed or could not be taken due to side effects or other reasons. TERN-701 is a tablet that is taken by mouth once a day.
The study has two parts. Depending on when they join the study, participants may be in either Part 1 or Part 2.
Part 1 is called a “Dose Escalation” in which at least 4 different dose levels of TERN-701 will be evaluated one at a time, starting at the lowest dose and increasing to higher doses. The purpose of Part 1 is to identify safe and effective doses of TERN-701 to further evaluate in Part 2.
Part 2 is called a “Dose Expansion”, where TERN-701 will be further evaluated in a larger group of participants.All patients taking part in this study will receive TERN-701 daily. The study is planned to involve approximately 160 participants who have CML.
Not all participants will stay in the study for the same amount of time. The duration of treatment will depend on how well patients tolerate the study medications, if they are responding to the study medication or if other discontinuation criteria are met.
This study involves procedures such as: physical examinations; collection of vital signs; electrocardiograms (ECGs); and collection of blood and urine. Bone marrow biopsies will only be performed if required as part of the patient's standard care.
REC name
West Midlands - Edgbaston Research Ethics Committee
REC reference
25/WM/0163
Date of REC Opinion
30 Sep 2025
REC opinion
Further Information Favourable Opinion